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Abstract Human brain tissue contains various alcohol
dehydrogenase (ADH) isoenzymes and possess also alde-
hyde dehydrogenase (ALDH) activity. In our last experi-
ments we have shown that ADH and ALDH are present
also in the brain tumour cells. Moreover the activities of
total ADH and class I isoenzymes were significantly higher
in cancer tissue than healthy cells. It can suggests that these
changes may be reflected by enzyme activity in the serum
of patients with brain cancer. Serum samples were taken
for routine biochemical investigation from 62 patients
suffering from brain cancer (36 glioblastoma, 26 menin-
gioma). For the measurement of the activity of class I and
II ADH isoenzymes and ALDH activity, the fluorometric
methods were used. The total ADH activity and activity of
class III and IV isoenzymes were measured by the photo-
metric method. A statistically significant increase of class I
alcohol dehydrogenase isoenzymes was found in the sera of
patients with brain cancer. The median activity of this class
isoenzyme in the patients group increased about 24 % in
the comparison to the control level. The total alcohol
dehydrogenase activity was also significantly higher
(26 %) among patients with brain tumour than healthy
ones. The activities of other tested ADH isoenzymes and
total ALDH were unchanged. The increase of the activity
of total ADH and class I alcohol dehydrogenase isoenzyme
in the sera of patients with brain cancer seems to be caused
by the release of this isoenzyme from tumour’s cells.
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Introduction
Malignant tumours of the brain are accounting for
approximately 2 % of all cancers in adults. Approximately
4,400 people are newly diagnosed with a brain tumour each
year in the developed countries. Primary brain cancers have
attracted increased attention in recent decades because,
although the survival rate continues to remain poor, there
are several reports suggesting an increasing trend in inci-
dence rates [1]. It is characterized by relatively late stage of
diagnosis. Therefore it is important to find markers that
may be helpful for diagnosing of brain cancer. The best
solution for the diagnosis of patients with central nervous
system (CNS) tumours could be easily available biomark-
ers, which could be useful for the management of CNS
neoplasms.
Some investigations have shown that alcohol dehydro-
genase (ADH) and aldehyde dehydrogenase (ALDH) are
present in the cells of human brain tissues [2, 3]. ADH and
ALDH, the enzymes responsible for metabolism of many
biological substances such as ethanol, serotonin, retinol,
exist in multiple molecular forms that have been grouped
into several classes, which display tissue specificity [4]. In
previous study we have shown that ADH and its isoen-
zymes and ALDH are present in the brain cancer cells.
Moreover the total activities of alcohol dehydrogenase and
class I ADH isoenzymes were significantly higher in cancer
tissues than in healthy brain cells [5]. We hypothesized that
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changed activities of these enzymes in the cancer cells can
play role in carcinogenesis and would be reflected in the
serum. In this study we investigated the activity of alcohol
dehydrogenase and its isoenzymes and the total activity of
ALDH in the sera of patients with brain cancer.
Materials and Methods
Patients
The protocol was approved by the Human Care Committee
of the Medical University in Bialystok, Poland (Approval
Nr R-I-002/460/2011). All patients gave informed consent
for the examination.
Serum samples were taken for routine biochemical
investigations from 62 patients suffering from brain
tumours (35 males and 27 females, range 30–77 years). All
tumors patients were identified from January 2011–
December 2012 in Department of Neurosurgery Medical
University of Bialystok (Poland). Among the cancer
patients, 36 patients (21 men and 15 women) suffering
from glioblastoma and 26 patients (14 men, 12 women) had
meningioma. The tumors were histopathologically classi-
fied according to World Health Organization criteria. We
have created the following groups, depending on the
location of the tumor: the frontal lobe, temporal lobe,
parietal lobe, cerebellum. Classification was based on
preoperative computed tomography (CT) and magnetic
resonance imaging scans. Preoperative functional status of
the patient was evaluated with the Karnofsky Performance
Status Scale. Preoperative MRI was used to determine
tumor volumes. None of the patients had received che-
motherapy or radiotherapy before samples collection. All
of the patients drank alcohol occasionally and self-reported
an intake of \25 g of ethanol per week. The clinicopath-
ological characteristics of the patients are shown in
Table 1.
Serum samples were also obtained from 120 healthy
subjects (control group, 70 males, 50 females, aged
35–65 years). Control groups were selected from healthy
community residents who attend the hospitals for routine
physical check-ups at the Department of Preventive Med-
icine. One and all were volunteers and were defined as
those with normal results of all physical, blood examina-
tions and CT of the brain. Before the examinations control
group had not consumed alcohol almost 1 months and
ethanol did not exist in serum samples of any subject when
it was collected.
Biochemical Assays
Determination of Total ADH Activity
Total ADH activity was estimated by the photometric
method with p-nitrosodimethylaniline (NDMA) as a sub-
strate [6]. The reaction mixture (2 ml) contained 0.1 ml of
serum and 1.8 ml of a 26 lM solution of substrate in 0.1 M
of sodium phosphate buffer, pH 8.5 and 0.1 ml of a mixture
containing 0.25 M n-butanol and 5 mM NAD. The reduc-
tion of NDMA was monitored at 440 nm on a Shimadzu
UV/VIS 1202 spectrophotometer (Shimadzu Europa
GmbH, Duisburg, Germany).
Determination of Total ALDH Activity
Aldehyde dehydrogenase activity was measured using the
fluorogenic method based on the oxidation of 6-methoxy-2-
naphtaldehyde to the fluorescent 6-methoxy-2 naphtoate
[7]. The reaction mixture contained 60 ll of serum, 60 ll
of substrate, 20 ll of 11.4 mM NAD and 2.8 ml of 50 mM
of sodium phosphate buffer, pH 8.5. The mixture contained
also 50 ll of a 12 mM solution of 4-methylpyrazole as a
specific inhibitor of ADH activity. The fluorescence was
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read at excitation wavelength 310 and emission wavelength
360 nm.
Determination of Class I and II ADH Isoenzymes
Class I and II alcohol dehydrogenase isoenzyme activity
were measured using fluorogenic substrates (4-methoxy-1-
naphthaldehyde for class I and 6-methoxy-2-naphthalde-
hyde for class II) in reduction reaction according to
Wierzchowski [8]. The assays were performed in a reaction
mixture containing a serum (60 ll), substrate (150 ll of
300 lM), NADH (100 ll of 1 mM) and 0, 1 M of sodium
phosphate buffer, pH 7.6 (2.69 ml) in conditions previ-
ously described [9]. The measurements were performed on
a Shimadzu RF–5301 spectrofluorophotometer (Shimadzu
Europa GmbH, Duisburg, Germany) at excitation wave-
length 316 nm for both substrates and emission of 370 nm
for class I and 360 nm for class II isoenzymes.
Determination of Class III ADH Isoenzyme
The assay mixture for class III of alcohol dehydrogenase
activity contained a serum (100 ll), n–octanol as a sub-
strate (31 ll of 1 mM), NAD (240 ll of 1.2 mM) in 0.1 M
NaOH-glycine buffer pH of 9, 6 [10]. The reduction of
NAD was monitored at 340 nm and 25 C on a Shimadzu
UV/VIS 1202 spectrophotometer.
Determination of Class IV ADH Isoenzyme
The assay mixture for class IV of alcohol dehydrogenase
activity contained a serum (50 ll), m–nitrobenzaldehyde as
a substrate of (132 ll of 80 lM), NADH (172 ll of
86 lM) in 0.1 M sodium phosphate buffer pH 7.5 [11]. The
oxidation of NADH was monitored at 340 nm and 25 C
on a Shimadzu UV/VIS 1202 spectrophotometer.
Statistical Analysis
A preliminary statistical analysis (Chi square test) revealed
that the distribution of ADH and ALDH activities did not
follow a normal distribution. Consequently, the Wilcoxon’s
test was used for statistical analysis. Data were presented as
median, range and mean values. Statistically significant
differences were defined as comparisons resulting in
p \ 0.05.
Results
The activities of alcohol dehydrogenase, aldehyde dehy-
drogenase and isoenzymes of alcohol dehydrogenase in the
sera are demonstrated in Table 2. The total activity of
alcohol dehydrogenase was significantly higher (about
26 %) in the serum of patients with brain cancer than in
healthy subjects. The median total activity of ADH was
895 mU/l in patients group and 664 mU/l in control group.
The analysis of ALDH activity did not indicated significant
difference between total tested group and healthy controls.
The comparison of ADH isoenzymes activities showed that
the highest difference was exhibited by class I ADH. The
median activity of this class isoenzyme in the total cancer
group increased about 24 % (1.77 mU/l) in comparison to
the control level (1.35 mU/l). This increase was statisti-
cally significant. The other tested classes of ADH isoen-
zymes had higher activities in the serum of patients with
brain cancer, but the differences were not statistically
significant in all patients groups (p [ 0.05).
The analysis of ADH, ALDH and ADH isoenzymes
activities in the serum did not indicate significant differ-
ences between patients with glioblastoma and meningioma.
The analysis of ADH, ALDH and ADH isoenzymes
activities showed lack of statistically significant difference
depending on the location of the tumor (Table 3).
Discussion
Brain tumours in adults are a rare diseases from which
survival is generally poor compared to many other cancers.
However survival chances have improved gradually over
the last 30 years. The length of survival following diag-
nosis of a brain tumour is dependent on the age of the
patient, histologic subtype, grade of the tumour, and pre-
senting symptoms [12]. Therefore it is very important to
find markers which would detect a malignant cell trans-
formation as early as it is possible. Tumour markers should
be synthesized and excreted by tumour tissues [13]. Cur-
rently, except for rare germ cell tumors, there is a lack of
knowledge on biochemical markers for CNS neoplasms.
The data that have been published concerning the
localization and activity of different ADH classes in the
brain are partially contradictory. Some researchers dem-
onstrated that only ADH III is present in the brain [14, 15].
Expression of ADH I and ADH IV mRNA in the adult
brain has been claimed by study using partially hydrolyzed
riboprobe in situ hybridization. The authors found ADH I
and ADH IV in cerebellar granule cells and different
regions of cerebral cortex [4]. Thus human brain express
mainly isoenzymes of three classes of alcohol dehydroge-
nase: I, III, and IV. In our previous study we have found
that alcohol dehydrogenase isoenzymes and aldehyde
dehydrogenase are present in the brain cancer cells.
Moreover we also shown that the total activity of ADH in
cancer tissue is about 28 % higher than that in healthy
brain tissues and there is no statistical differences in the
Neurochem Res (2014) 39:2313–2318 2315
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activity of aldehyde dehydrogenase between brain healthy
and cancerous tissues. In addition the data of the same
study showed that only the activity of class I ADH is
significantly higher in cancer than in healthy brain cells.
ADH I is the main ethanol-metabolizing isoenzyme class in
the brain. The other tested classes of ADH isoenzymes had
higher activities in cancer tissue than in healthy brain cells,
but these differences were not statistically significant [5].
In present study we stated that the serum total alcohol
dehydrogenase activity has been significantly increased in
brain cancer. The significant increase of total activity of
ADH was positively correlated with ADH I so it indicates
that the cause of the significant increase of serum total
alcohol dehydrogenase in the course of brain cancer is an
elevation of class I ADH isoenzymes. The increases of
other ADH isoenzymes activities were not significant in the
Table 2 ADH and ALDH
activity in the sera of patients
with brain tumour
Data are expressed as mU/l
pa brain cancer versus control
pb glioblastoma versus control






Tested group ADH I ADH II ADH III ADH IV ADH Total ALDH
Median Median Median Median Median Median
Range Range Range Range Range Range
Range Mean Mean Mean Mean Mean
Brain cancer
(n = 62)
1.77 14.81 12.23 5.46 895 2.90
1.08–3.64 6.94–21.65 7.05–18.21 2.11–11.98 338–1,544 1.35–5.63
1.73 14.24 12.16 5.31 866 2.77
Glioblastoma
(n = 36)
1.79 14.96 12.55 5.64 924 3.02
1.11–3.64 7.25–21.65 7.62–18.21 2.36–11.98 366–1,544 1.48–5.63
1.76 14.55 12.33 5.40 901 2.88
Meningioma
(n = 26)
1.73 14.52 12.14 5.32 880 2.84
1.08–3.32 7.25–20.48 7.05–18.03 2.11–11.56 338–1,488 1.35–5.14
1.71 14.18 12.05 5.21 856 2.68
Control (n = 120) 1.35 14.45 11.96 5.22 664 2.74
0.96–2.83 6.06–19.82 7.22–17.48 2.04–11.75 267–1,345 1.21–5.36
1.31 14.02 11.35 5.08 740 2.58
pa \ 0.001* pa = 0.327 pa = 0.296 pa = 0.436 pa \ 0.001* pa = 0.274
pb \ 0.001* pb = 0.366 pb = 0.346 pb = 0.372 pb \ 0.001* pb = 0.369
pc \ 0.001* pc = 0.258 pc = 0.377 pc = 0.348 pc \ 0.001* pc = 0.361
pd = 0.437 pd = 0.436 pd = 0.281 pd = 0.274 pd = 0.423 pd = 0.285
Table 3 The comparison of
ADH isoenzymes and ALDH
activity in the serum of patients
with brain cancer depending on
the localization of tumour
Data are expressed as mU/l
Tested group ADH I ADH II ADH II ADH IV ADH Total ALDH
Median Median Median Median Median Median
Range Range Range Range Range Range
Mean Mean Mean Mean Mean Mean
Frontal lobe (n = 16) 1.82 14.85 12.42 5.51 906 2.98
1.21–3.47 7.24–21.65 7.34–18.04 2.18–11.77 378–1,544 1.48–5.63
1.71 14.47 12.27 5.40 895 2.84
Temporal lobe (n = 24) 1.76 14.58 12.17 5.42 881 2.85
1.15–3.36 7.03–21.14 7.16–17.86 2.23–11.58 361–1,492 1.48–5.28
1.68 14.22 12.09 5.28 870 2.74
Parietal lobe (n = 16) 1.70 14.55 12.11 5.35 876 2.87
1.08–3.03 6.94–20.95 7.05–17.67 2.11–11.61 338–1,465 1.35–5.22
1.62 14.31 12.03 5.16 862 2.70
Cerebellum (n = 6) 1.88 14.76 12.47 5.48 899 2.94
1.31–3.64 7.12–21.30 7.46–18.21 2.28–11.98 353–1,518 1.52–5.47
1.80 14.38 12.30 5.36 883 2.88
Control (n = 120) 1.35 14.45 11.96 5.22 664 2.74
0.96–2.83 6.06–19.82 7.22–17.48 2.04–11.75 267–1,345 1.21–5.36
1.31 14.02 11.35 5.08 740 2.58
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serum of patients with brain cancer. In our opinion low
activity of ADH II, III and IV can be explained by low
activity of these isoenzymes in the brain cancer cells and
by low secretion into the sera. Aldehyde dehydrogenase is
present in the brain although the activity of ALDH seems
to be disproportionaly low to ADH activity. The serum
levels of aldehyde dehydrogenase were not significantly
higher in patients with brain tumour in comparison to
healthy group.
The analysis of ADH, ALDH and ADH isoenzymes
activities in the serum did not indicate significant differ-
ences between patients with glioblastoma and meningioma.
These data are in accordance with our previous study. The
histological differences of cancers did not effect the
activity of tested enzymes. We have found that the activity
of ADH and ALDH in cancer tissues of glioblastoma did
not differ from that of meningioma. It is surprising,
because they differ in the degree of malignancy, the origin
of the cells and etiology.
Alcohol dehydrogenase I activity was found in the cer-
ebellar granule cells and Purkinje cells, in the hippocampal
formation, cerebellum and other regions of cerebral cortex
[4]. By Western blot analysis and immunohistochemistry,
highest ADH III levels were found in cerebellum and
hippocampus and lower concentrations in other parts of
cortex cerebri [16]. In this study, we examined the
dependence of the ADH activity in serum and localization
of brain tumor. Analyzing the activity of ADH, ALDH and
ADH isoenzymes we do not find the significant differences
depending on the location of the tumor in the brain.
In our previous investigations we have presented data
that the activity of class I ADH (the principal class of ADH
isoenzymes in the liver and colon is significantly higher in
cancer cells than in healthy liver or colorectum [17, 18].
Therefore, the activity of class I alcohol dehydrogenase
isoenzymes was significantly elevated in the serum of
patients with liver and colorectal cancer [19, 20].
In conclusion, we can state that the increase of the
activity of total ADH and class I alcohol dehydrogenase
isoenzyme in the sera of brain cancer patients seems to be
caused by release of this isoenzyme from cancer cells to
blood and probably total ADH and ADH I determination in
serum could be helpful for diagnostic of CNS tumours but
further investigations and confirmation by a prospective
study are necessary.
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